Elucidating the specific pharmacological mechanism of action (MOA) of naturally developing compounds can be challenging. Whilst Tarselli et al. (60) created the first de novo synthetic pathway to conolidine and showcased this naturally taking place compound efficiently suppresses responses to both chemically induced and inflammation-derived pain, the pharmacologic focus https://janea321dfg2.shoutmyblog.com/profile